紫杉烷类药物在绒毛膜癌治疗中的应用:病例报道和文献回顾  

The use of taxanes in choriocar cinoma;a case reportand review of the literature

作　　者：Joshua A.M. Carter J.R. Beale P. 马向东 

机构地区：[1]De-partment ofMedicalOncolog y,SydneyCancerCentre,Roy-alPrinceAlfredHospital,Sydney,N SW2050,Australia

出　　处：《世界核心医学期刊文摘（妇产科学分册）》2005年第2期39-39,共1页Core Journal in Obstetrics/Gynecology

摘　　要：Background.Both preclinical data a nd case reports sup-port the use of taxanes for high-risk metastatic choriocar-cinoma.Case.We report the case of a 31-year-old with metastatic choriocarcinoma who req uired 3rd-line treatment with a paclitaxel-cispaltin-based regimen.She achieved a complete response and remains relap se-free 21months after her last dose of chemotherapy.Conclusion.The literaturesuggests that paclitaxel contribut es significantly to the treatment of choriocarcinoma and it s use should be explored further.This is the first case report formally reporting its combinationwith cisplatin.Background.Both preclinical data a nd case reports sup-port the use of taxanes for high-risk metastatic choriocar-cinoma.Case.We report the case of a 31-year-old with metastatic choriocarcinoma who req uired 3rd-line treatment with a paclitaxel-cispaltin-based regimen.She achieved a complete response and remains relap se-free 21months after her last dose of chemotherapy.Conclusion.The literaturesuggests that paclitaxel contribut es significantly to the treatment of choriocarcinoma and it s use should be explored further.This is the first case report formally reporting its combinationwith cisplatin.

关 键 词：绒毛膜癌 紫杉烷类药物 文献回顾 顺铂联合 末次化疗 临床前 

分 类 号：R737.33[医药卫生—肿瘤]